Possible Participation of Tumoricidal Macrophages in the Therapeutic Effect of Bleomycin on a Transplantable Rat Fibrosarcoma

Cancer Research

Volumn 46, Issue 2, 1986, Pages 684-688

  Morikawa, Kiyoshi ^a   Hosokawa, Masuo ^a   Hamada, Jun Ichi ^a   Xu, Zhen Yi ^a   Kobayashi, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARRAGEENAN; IDOXURIDINE I 125; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; FIBROSARCOMA; INTOXICATION; INTRAPERITONEAL DRUG ADMINISTRATION; MACROPHAGE ACTIVATION; NONHUMAN; PERITONEUM; PERITONEUM CELL; PRELIMINARY COMMUNICATION; PRIORITY JOURNAL; RAT; SPLEEN; SPLEEN CELL; T LYMPHOCYTE; THERAPY;

ANIMALS; BLEOMYCIN; CARRAGEENAN; CYTOTOXICITY, IMMUNOLOGIC; MACROPHAGES; PERITONEAL CAVITY; RATS; SARCOMA, EXPERIMENTAL; SPLEEN;

EID: 0022644201     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Fujii, H., Mihich, E., and Pressman, D. Differentia tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. II. Increased expression of tumor–associatedantigenson subline cells recognized by serologieand transplantation methods. J. Nati. Cancer Inst., 62:1503-1510,1979.
2. Segerting, M., Ohanian, S. H., and Borsos, T. Chemotherapeuticdrugs increase killing of tumor cells by antibody and complement. Science (Wash. DC), 788: 55-57,1975.
3. Coletta, F., Peri, G., Villa, A., and Mantovani, A. Rapid killing of actinomycin D-treated tumor cells by human mononuclearcells. I. Effector belongs to the monocyte-macrophagelineage. J. Immunol., 732: 936-944,1984.
4. Ehrke, M. J., Cohen, S. A., and Mihich, E. Selective effects of Adriamycin on murine host defense systems. Immunol. Rev., 65: 55-78,1982.
5. Parker, D., and Turk, J. L. Potentiation of T–lymphocytefunction by bteomycin. Immunopharmacotogy,7:109-113,1984.
6. Hengst, J. C. D., Mokyr, M. B., and Dray, S. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res., 47:2163-2167,1981.
7. Mizushima, Y., Sendo, F., Miyake, T., and Kobayashi, H. Augmentation of specific cell mediated immune responses to tumor cells in tumor–bearing rats pretreated with the antileukemiadrug busulfan. J. Natl. Cancer Inst., 66: 659-665,1981.
8. Mizushima, Y., Sendo, F., Takeichi, N., Hosokawa, M., and Kobayashi, H. Enhancementof antitumor transplantation resistance in rats by appropriately timed administration of busulfan. Cancer Res., 41: 2917-2921,1981.
9. Morikawa, K., Hosokawa, M., Mamada,J., Sugawara. M., and Kobayasghi,H. Host-mediated therapeutic effects produced by appropriately timed administration of bleomycmon a rat fibrosarcoma. Cancer Res., 45:1502-1506, 1985.
10. North, R. J. Cyclophosphamide-facilitatedadoptive immunotherapyof an established tumor depends on elimination of tumor-induced suppressor T-cells. J. Exp. Med., 55:1063-1074,1982.
11. Schultz, R. M., Pavlidis, N. A., Chiligos, M. A., and Weiss, J. F. Effects of whole body X-irradiation and cyctophosphamide treatment on induction of macrophage tumoricidal function in mice. Cell. Immunol.,38: 302-309,1978.
12. Stoychkov, J. N., Schultz, R. M., Chiligos, M. A., Pavlidis, N. A., and Goldin, A. Effects of Adriamycin and cyctophosphamidetreatment on induction of macrophagecytotoxic function in mice. Cancer Res., 39: 3014-3017,1979.
13. Riccardi, C., Puccetti, P., Santoni, A., Herberman,R. B., and Bonmassar, E. Adriamycin-inducedanti tumor response in lethally irradiated mice. Imrnuno pharmacotogy, 7; 211-220,1979.
14. Haskill, J. S. Adriamycin-activatedmacrophages as tumor growth inhibitors. Cancer Res., 41: 3852-3856,1981.
15. Kleinerman, E.S. Zwelling L.A. Scwartz R. and Muchmore A.V. effect of L-phenylalanine mustard, adriamycin, actinomycin d, and 4' (9-acridinylamino) methanesulfon-m-anisidideon naturally occurring human spontaneous monocyte-mediatedcytotoxicity. Cancer Res., 42:1692-1695,1982.
16. Ogura, T., Shindo, H., Shinzato, O., Namba, M., Masuo, T., Inoue, T., Kishimoto, S., and Yamamura. Y. In vitro tumor cell killing by peritoneal macro phages from mitomyoin-C-treated rats. Cancer Immunol. Immunother, 73: 112-117,1982.
17. Umezawa, H. Bteomycin: discovery, chemistry, and action. Gann Monogr. Cancer Res., 79: 3-36,1976.
18. Tmg, C. C., Park, J. Y., Nunn, M. E., and Herberman, R. B. Comparison of three isotopie assays of cell-mediatedcytotoxicity against mouse tumor cells. I. Basic parameters:baselinecontrols, target cells,and methods of calculation. J. Natl. Cancer Inst., 58: 323-330,1977.
19. Ishii, Y., Koshiba, H., Yamaoka, H., and Kikuchi, K. Rat T lymphocyte specific antigens and their cross reactivity with mouse T-cells. J. Immunol., 777: 497–503,1978.
20. Thomson, A. W., Wilson, A. R., Cruichshank, W. J., and Home, C. H. W. Evaluation of carrageenanas an immunosuppressiveagent and mediator of intravascularcoagulation. Biomedicine(Paris),24:102-106,1976.
21. Fidter,I. J. Activation in vitro of mouse macrophagesby syngeneic,altogeneic, or xenogeneiclymphocytesupematants. J. Natl. CancerInst., 55:1159-1163, 1975.
22. Kripke. M. L., Budrnen. M. B., and Fidler, I. J. Production of specific macro phage activating factor by lymphocytes from tumor bearing mice. Cell. Immunol., 30: 341-352,1977.
23. Webb, P. J., Brooks, C. G., and Baldwin, R. W. Macrophage like suppressor cells in rats. II. Evidencefor a quantitative rather than a qualitative change in tumor bearing animals. Cell. Immunol.,52: 381-394,1980.
24. Kleinerman, E. S., Zwelling, L. A., and Muchmore, A. V. Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by c/s-diamminedichloroplatinum(ll).Cancer Res., 40: 3099-3102.1982.
25. Hozumi, M. Fundamentals of chemotherapy of myeloid leukemia by induction of leukemiacell differentiation. Adv. Cancer Res., 38:121-169,1983.